Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

P
Patrick Loehrer, MD

Primary Investigator

Overview

The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Ductal Adenocarcinoma, pancreatic cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria

Untreated locally advanced PDAC
Histologically or cytologically confirmed PDAC
Adequate organ function
Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of study treatment.

Updated on 20 Nov 2022. Study ID: 1811447298 (IUSCC-0664)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center